期刊
NUTRIENTS
卷 15, 期 5, 页码 -出版社
MDPI
DOI: 10.3390/nu15051285
关键词
COVID-19; lactoferrin; randomized; placebo-controlled; multicenter; double-blind clinical trial
Bovine lactoferrin, as a nutritional supplement, does not improve the clinical course of hospitalized patients with moderate-to-severe COVID-19. The LAC trial showed that there were no significant differences in the outcomes between lactoferrin and placebo groups, including death or ICU admission rate, and discharge or NEWS2 <= 2 within 14 days. Although lactoferrin demonstrated excellent safety and tolerability, its use in this patient population is not supported.
As lactoferrin is a nutritional supplement with proven antiviral and immunomodulatory abilities, it may be used to improve the clinical course of COVID-19. The clinical efficacy and safety of bovine lactoferrin were evaluated in the LAC randomized double-blind placebo-controlled trial. A total of 218 hospitalized adult patients with moderate-to-severe COVID-19 were randomized to receive 800 mg/die oral bovine lactoferrin (n = 113) or placebo (n = 105), both given in combination with standard COVID-19 therapy. No differences in lactoferrin vs. placebo were observed in the primary outcomes: the proportion of death or intensive care unit admission (risk ratio of 1.06 (95% CI 0.63-1.79)) or proportion of discharge or National Early Warning Score 2 (NEWS2) <= 2 within 14 days from enrollment (RR of 0.85 (95% CI 0.70-1.04)). Lactoferrin showed an excellent safety and tolerability profile. Even though bovine lactoferrin is safe and tolerable, our results do not support its use in hospitalized patients with moderate-to-severe COVID-19.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据